Product Pipeline

Xel's pharmaceutical product development activities are focused on two key targeted drug delivery fields: Transdermal and Controlled Release. Currently, Xel has developed XEL 001HP, a Huperzine A transdermal patch (a powerful, highly selective and reversible inhibitor of acetyl cholinesterase) for the treatment of Alzheimer's Disease and XEL 002BP, a Bulleyaconitine transdermal patch (a non opioid dependence, long-lasting analgesic agent with anti-inflammation effect) for pain management, both are poised for IND filing in the US. In addition, XEL 001HP has obtained IND approval from Chinese SFDA and a Phase I clinical trial is currently underway in China.

Xel has several drug candidates in preclinical stages as shown below; all of which are currently available for co-development and licensing opportunities: